Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMA3DKO)

• Drug Name: RIST4721 Drug Info
• Synonyms: vimnerixin; AZD4721; RIST4721; AZD-4721; RIST-4721; X09ORN2BF0; 1418112-77-2; UNII-X09ORN2BF0; AZD-4721 [WHO-DD]; 1-Azetidinesulfonamide, N-(6-((1R,2S)-2,3-dihydroxy-1-methylpropoxy)-2-(((4-fluorophenyl)methyl)thio)-4-pyrimidinyl)-3-methyl-; vimnerixin [INN]; Azd 4721; CHEMBL5095217; SCHEMBL14579049; GTPL12100; AZD 4721 [WHO-DD]; AZD4721;RIST4721; AKOS040756752; compound 4 [WO2019055509A1]; MS-28748; HY-145640; CS-0377236; F83913; N-(6-{[(2R,3S)-3,4-dihydroxybutan-2-yl]oxy}-2-{[(4-fluorophenyl)methyl]sulfanyl}pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide; N-[6-[(1R,2S)-2,3-Dihydroxy-1-methylpropoxy]-2-[[(4-fluorophenyl)methyl]thio]-4-pyrimidinyl]-3-methyl-1-azetidinesulfonamide; N-[6-[(2R,3S)-3,4-dihydroxybutan-2-yl]oxy-2-[(4-fluorophenyl)methylsulfanyl]pyrimidin-4-yl]-3-methylazetidine-1-sulfonamide

Indication

Disease Entry	ICD 11	Status	REF
Hidradenitis suppurativa	ED92.0	Phase 2	[1]
Palmoplantar pustulosis	EA90.42	Phase 2	[2]

• Cross-matching ID:
  PubChem CID: 71209600
  TTD Drug ID: DMA3DKO

Molecule-Related Drug Atlas

Drug(s) Targeting C-X-C chemokine receptor type 2 (CXCR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[4]
Clotrimazole	DMMFCIH	Cutaneous candidiasis	1F23.14	Approved	[5]
Reparixin	DMVBA7I	Pancreatic islet transplantation failure	NE84	Phase 3	[4]
SCH-527123	DMPUAOE	Chronic obstructive pulmonary disease	CA22	Phase 2	[6]
SB-265610	DM8TKG5	Asthma	CA23	Phase 2	[7]
AZD-5069	DM3JSFK	Asthma	CA23	Phase 2	[8]
PS-938285	DMHZIFJ	Chronic obstructive pulmonary disease	CA22	Phase 2	[9]
GSK1325756	DMA6RBF	Chronic obstructive pulmonary disease	CA22	Phase 2	[10]
SB-656933	DMCY785	Chronic obstructive pulmonary disease	CA22	Phase 2	[11]
SX-682	DMHMG6X	Melanoma	2C30	Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-X-C chemokine receptor type 2 (CXCR2)	TT30C9G	CXCR2_HUMAN	Antagonist	[3]

References

• [1] ClinicalTrials.gov (NCT05348681) A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Hidradenitis Suppurativa. U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT05194839) A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Palmoplantar Pustulosis. U.S.National Institutes of Health.
• [3] A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis. Dermatol Ther (Heidelb). 2021 Dec;11(6):2179-2193.
• [4] 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
• [5] Mode of action of clotrimazole: implications for therapy. Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):939-44.
• [6] CXCR2 Antagonist MK-7123.A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med.2015 May 1;191(9):1001-11.
• [7] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
• [8] Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther. 2015 May;353(2):340-50.
• [9] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
• [10] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [11] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [12] Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clin Cancer Res. 2020 Mar 15;26(6):1420-1431.